Author

J. Bernhagen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Assay:proteomics· 2 Organism:Arabidopsis· 1 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Kapurniotu· 3 shared C. Weber· 3 shared M. Brandhofer· 3 shared O. El Bounkari· 3 shared A. Hoffmann· 2 shared C. Kontos· 2 shared C. M. Krammer· 2 shared D. Sinitski· 2 shared

Activity by Year

2021-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Kapurniotu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Structures of Arabidopsis thaliana MDL Proteins and Synergistic Effects with the Cytokine MIF on Human Receptors

L. Spiller, M. Ramu, F. Leissing, J. Basquin, P. Bourilhon, D. Sinitski, M. Brandhofer, S. C. Levecque, B. Sabelleck, R. Feederle, A. Flatley, R. Panstruga, J. Bernhagen, E. Lolis

A. thaliana MDLs and human MIF interact to synergistically activate CXCR2 and CXCR4 signaling.

bioRxiv · Jan 30, 2023 · PreprintImmunology

MIF-2/D-DT is an atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

O. El Bounkari, C. Zan, J. Wagner, E. Bugar, P. Bourilhon, C. Kontos, M. Zarwel, D. Sinitski, J. Milic, Y. Jansen, W. Kempf, L. Maegdefessel, A. Hoffmann, M. Brandhofer, R. Bucala, , J. Bernhagen

This study identifies MIF-2 as an atherogenic chemokine that promotes atherosclerosis and hepatic lipogenesis by acting through CXCR4 and SREBP pathways.

bioRxiv · Dec 28, 2021 · PreprintImmunology

Link between aging and atheroprotection in Mif-deficient atherosclerotic mice

C. M. Krammer, B. Yang, S. Reichl, V. Bolini, C. Schulte, H. Noels, O. El Bounkari, A. Kapurniotu, C. Weber, M. Sarajo, J. Bernhagen

This study investigates how Mif deficiency affects atheroprotection in aging Apoe-/- mice, finding that atheroprotective effects diminish with age.

bioRxiv · Dec 14, 2021 · PreprintImmunology

Heterocomplexes between the Atypical Chemokine MIF and the CXC-Motif Chemokine CXCL4L1 Regulate Inflammation and Thrombus Formation

M. Brandhofer, A. Hoffmann, X. Blanchet, E. Siminkovitch, A.-K. Rohlfing, O. El Bounkari, J. A. Nestele, A. Bild, C. Kontos, K. Hille, V. Rohde, A. Froehlich, J. Golemi, O. Goekce, C. M. Krammer, , J. Bernhagen

This study identifies a novel interaction between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1, showing that their heterocomplex formation modulates inflammation and thrombus formation.

bioRxiv · Nov 26, 2021Immunology

CCL2/CCR2 inhibition in atherosclerosis: a meta-analysis of preclinical studies

L. Zivkovic, Y. Asare, J. Bernhagen, M. Dichgans, M. K. Georgakis

This paper meta-analyzes preclinical studies on CCL2/CCR2 inhibition in atherosclerosis, finding it reduces lesion size and stabilizes plaques across multiple vascular sites and models.

bioRxiv · Apr 16, 2021 · PreprintImmunology